10,406 Shares in Vera Therapeutics, Inc. $VERA Purchased by Perigon Wealth Management LLC

Key Points

• Perigon Wealth Management LLC acquired 10,406 shares of Vera Therapeutics, Inc. valued at approximately $245,000 as part of their institutional investment strategy.
• Analysts maintain a consensus rating of "Moderate Buy" for Vera Therapeutics, with seven analysts rating it a Buy and two a Hold, alongside a target price of $63.00.
• Vera Therapeutics reported a quarterly earnings loss of ($1.20) EPS, missing consensus estimates, indicating challenges in achieving profitability.

Perigon Wealth Management LLC purchased a new stake in shares of Vera Therapeutics, Inc. (NASDAQ:VERA - Free Report) in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 10,406 shares of the company's stock, valued at approximately $245,000.

A number of other large investors have also added to or reduced their stakes in the company. Price T Rowe Associates Inc. MD grew its holdings in shares of Vera Therapeutics by 8.6% in the first quarter. Price T Rowe Associates Inc. MD now owns 4,754,832 shares of the company's stock valued at $114,212,000 after purchasing an additional 377,783 shares in the last quarter. Vestal Point Capital LP lifted its position in Vera Therapeutics by 132.6% during the first quarter. Vestal Point Capital LP now owns 2,500,000 shares of the company's stock valued at $60,050,000 after purchasing an additional 1,425,000 shares during the last quarter. T. Rowe Price Investment Management Inc. grew its stake in shares of Vera Therapeutics by 18.4% in the 1st quarter. T. Rowe Price Investment Management Inc. now owns 1,675,367 shares of the company's stock worth $40,243,000 after buying an additional 260,188 shares in the last quarter. Deutsche Bank AG increased its holdings in shares of Vera Therapeutics by 10.2% in the 1st quarter. Deutsche Bank AG now owns 892,859 shares of the company's stock worth $21,446,000 after buying an additional 82,483 shares during the last quarter. Finally, MPM Bioimpact LLC raised its position in shares of Vera Therapeutics by 61.3% during the 1st quarter. MPM Bioimpact LLC now owns 415,719 shares of the company's stock valued at $9,986,000 after buying an additional 157,931 shares in the last quarter. Institutional investors own 99.21% of the company's stock.

Analyst Ratings Changes

VERA has been the subject of several recent research reports. Guggenheim reiterated a "buy" rating on shares of Vera Therapeutics in a research report on Tuesday, June 3rd. JPMorgan Chase & Co. dropped their target price on Vera Therapeutics from $56.00 to $53.00 and set an "overweight" rating for the company in a report on Thursday, August 7th. Cantor Fitzgerald restated an "overweight" rating on shares of Vera Therapeutics in a report on Thursday, September 18th. Wolfe Research restated a "peer perform" rating on shares of Vera Therapeutics in a research report on Monday, August 4th. Finally, Scotiabank reiterated an "outperform" rating on shares of Vera Therapeutics in a research report on Tuesday, June 3rd. Seven equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company's stock. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $63.00.

Vera Therapeutics Stock Performance

Shares of Vera Therapeutics stock opened at $29.06 on Wednesday. The company has a quick ratio of 17.03, a current ratio of 17.03 and a debt-to-equity ratio of 0.16. The stock's fifty day moving average is $23.00 and its two-hundred day moving average is $23.04. Vera Therapeutics, Inc. has a 52 week low of $18.53 and a 52 week high of $51.61. The company has a market capitalization of $1.85 billion, a PE ratio of -8.12 and a beta of 1.17.

Vera Therapeutics (NASDAQ:VERA - Get Free Report) last posted its quarterly earnings results on Tuesday, August 5th. The company reported ($1.20) EPS for the quarter, missing analysts' consensus estimates of ($0.82) by ($0.38). During the same period in the previous year, the company posted ($0.62) EPS. As a group, analysts expect that Vera Therapeutics, Inc. will post -2.89 earnings per share for the current year.

Vera Therapeutics Company Profile

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.

Want to see what other hedge funds are holding VERA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vera Therapeutics, Inc. (NASDAQ:VERA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.